KAS
BEAM icon

Kemnay Advisory Services’s Beam Therapeutics BEAM Stock Holding History

Kemnay Advisory Services’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Buy
911
+122
+15% +$3.68K ﹤0.01% 477
2026
Q1 		$18.8K Buy
+789
New +$21.9K ﹤0.01% 726

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Kemnay Advisory Services's BEAM Position: Q2 2026 in Review

Kemnay Advisory Services increased its Beam Therapeutics (BEAM) stake by 15% in Q2 2026, buying an estimated $3.68K and bringing the position to 911 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #477.

Kemnay Advisory Services first reported a position in BEAM in Q1 2026 and has held it in 2 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Kemnay Advisory Services held 911 shares of Beam Therapeutics worth $31.3K as of Q2 2026.
  • Kemnay Advisory Services bought 122 Beam Therapeutics shares in Q2 2026, an estimated $3.68K.
  • Beam Therapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #477 holding.
  • Kemnay Advisory Services first reported a position in Beam Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.